Analysis of immune-related adverse events and its correlation with efficacy of anti-PD-1 monotherapy in advanced non-small cell lung cancer
Background and purpose: With the increasing application of immune checkpoint inhibitors in lung cancer, immune-related adverse event (irAE) has attracted more and more attention. This study aimed to analyze the occurrence of irAE in patients receiving single-drug immunotherapy and the corr...
Main Author: | YI Weili , ZHAO Wencheng , HUANG Dongning , QIN Li , WU Xintian , ZHOU Fei , WU Fengying |
---|---|
Format: | Article |
Language: | English |
Published: |
Editorial Office of China Oncology
2021-03-01
|
Series: | Zhongguo aizheng zazhi |
Subjects: | |
Online Access: | http://www.china-oncology.com/fileup/1007-3639/PDF/20210307.pdf |
Similar Items
-
Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs
by: Atsuto Mouri, et al.
Published: (2021-08-01) -
Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis
by: Li Lin, et al.
Published: (2023-05-01) -
PD-1/PD-L1 inhibitor treatment and its impact on clinical imaging in non-small cell lung cancer: a systematic review and meta-analysis of immune-related adverse events
by: Nader Mohammed, et al.
Published: (2023-09-01) -
Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies
by: Xuwen Lin, et al.
Published: (2024-03-01) -
Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer
by: Ye Tao, et al.
Published: (2023-05-01)